Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension

Journal of Heart and Lung Transplantation

Volumn 31, Issue 7, 2012, Pages 735-743

  Sadushi Koliçi, Roela ^a   Skoro Sajer, Nika ^a   Zimmer, Daniel ^a   Bonderman, Diana ^a   Schemper, Michael ^a   Klepetko, Walter ^a   Glatz, Jutta ^b   Jakowitsch, Johannes ^a   Lang, Irene M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AOP Orphan Pharmaceuticals AG   (Austria)

Author keywords

long term treatment; pre capillary pulmonary hypertension; prostanoid therapy; severe pulmonary hypertension; sub cutaneous treprostinil

Indexed keywords

BOSENTAN; SILDENAFIL; UNIPROST;

ADULT; ARTICLE; CONTROLLED STUDY; DATA COLLECTION METHOD; DISEASE REGISTRY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INDEX; HUMAN; LONG TERM CARE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OVERALL SURVIVAL; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; REGISTER; SURVIVAL; WALKING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861841909     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2012.02.025     Document Type: Article

References (22)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54: S43-54.
3. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
4. Lang IM. Chronic thromboembolic pulmonary hypertension - not so rare after all. N Engl J Med 2004;350:2236-8. (Pubitemid 38669205)
5. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
6. Ulrich S, Speich R, Domenighetti G, et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly 2007;137:573-80.
7. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
8. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-55.
9. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72.
10. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55-66.
11. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4. (Pubitemid 34229650)
12. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
13. Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet 2008;47:611-8.
14. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6. (Pubitemid 26342716)
15. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101-21.
16. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43. (Pubitemid 43894997)
17. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203. (Pubitemid 44883856)
18. Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011;30:982-9.
19. Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5:483-9. (Pubitemid 46680679)
20. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122: 156-63.
21. Thenappan T, Palevsky HI. Long-term outcomes in pulmonary arterial hypertension. Int J Clin Pract Suppl 2009:42-4.
22. Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2009;49:490-500.